Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | CPA1 | P15085 | 2/20 | 0.60 |
| ▸ | CPB1 | P15086 | 1/20 | 0.60 |
| ▸ | CPA3 | P15088 | 1/20 | 0.60 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | ANPEP | P15144 | 3/20 | 0.55 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197907 | 1.00 | EPHX1 (0.64) | EPHX1CPA1CPB1CPA3CPB2 | |
| SCHEMBL123055 | 1.00 | EPHX1 (0.64) | EPHX1CPA1CPB1CPA3CPB2 | |
| Hydrochloric Acid SCHEMBL654577 | 0.98 | EPHX1 (0.61) | EPHX1CPA1CPB1CPA3CPB2 | |
| Hydrochloric Acid SCHEMBL654576 | 0.98 | EPHX1 (0.61) | EPHX1CPA1CPB1CPA3CPB2 | |
| Acetic Acid SCHEMBL6690172 | 0.94 | ALPI (0.58) | EPHX1CPA1CPB1CPA3CPB2 | |
| Trifluoroacetic Acid SCHEMBL1395876 | 0.91 | EPHX1 (0.53) | EPHX1CPA1CPB1CPA3CPB2 | |
| Trifluoroacetic Acid SCHEMBL6157790 | 0.91 | EPHX1 (0.53) | EPHX1CPA1CPB1CPA3CPB2 | |
| SCHEMBL29556848 | 0.89 | FFAR1 (0.55) | EPHX1CPA1CPB1CPA3CPB2 | |
| SCHEMBL2032416 | 0.89 | FFAR1 (0.55) | EPHX1CPA1CPB1CPA3CPB2 | |
| Hydrochloric Acid SCHEMBL1912599 | 0.87 | SRR (0.55) | EPHX1CPA1CPB1CPA3CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | claimed |
| CN-118845500-A | Silicon oxide nursing formula and preparation method thereof | 深圳简体美健康信息咨询有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | claimed |
| EP-4314017-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4314014-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4314016-A1 | CYCLIC CELL PENETRATING PEPTIDES | Entrada Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | claimed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | EPHX1 3471/4885CPA1 3400/4885CPB1 3196/4885 |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | EPHX1 2065/4885CPA1 348/4885CPB1 551/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | EPHX1 2065/4885CPA1 348/4885CPB1 551/4885 |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | EPHX1 2471/4885CPA1 482/4885CPB1 403/4885 |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | EPHX1 2065/4885CPA1 348/4885CPB1 551/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | EPHX1 3082/4885CPA1 3563/4885CPB1 3015/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | EPHX1 1622/4885CPA1 81/4885CPB1 59/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | EPHX1 2004/4885CPA1 933/4885CPB1 872/4885 |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | EPHX1 2322/4885CPA1 757/4885CPB1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.